Lung cancer in never-smokers exhibits distinct biological characteristics, often leading to late-stage diagnoses due to lack of screening. Targeted therapies, guided by molecular testing, offer ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Targeted protein degradation (TPD) therapy is a promising new class of targeted treatments. Based on a cell’s natural mechanism for eliminating diseased proteins, this therapy can combat hard-to-treat ...

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a phase 1/2 clinical study with a 42-month-long follow-up period, researchers ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...

Targeted therapies are medicines to treat cancer. They work differently than standard chemotherapy. Instead of killing all fast-growing cells or keeping them from dividing, targeted therapies work ...

IgA nephropathy (IgAN), or Berger’s disease, is a kidney condition that occurs when abnormal immunoglobulin A (IgA) antibodies trigger inflammation in the kidneys. Until recently, treatment for IgAN ...

Use of a novel proteomimetic nanoplatform for simultaneous delivery of antigens with adjuvants to impact tumor growth in multiple tumor models. This is an ASCO Meeting Abstract from the ASCO ...

The bone metastasis in solid tumors market is expanding due to rising incidences of metastasizing solid tumors like breast, prostate, lung cancer, and renal cell carcinoma. This growth is fueled by ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...